Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
Visual Abstract - <img class="highwire-fragment fragment-image" alt="Figure1" src="http://www.bloodjournal.org/content/bloodjournal/132/4/393/F1.medium.gif" width="440" height="294"/>Download figureOpen in new tabDownload powerpoint - - Ponati...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[26 July 2018]
|
| In: |
Blood
Year: 2018, Jahrgang: 132, Heft: 4, Pages: 393-404 |
| ISSN: | 1528-0020 |
| DOI: | 10.1182/blood-2016-09-739086 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1182/blood-2016-09-739086 Verlag, Volltext: http://www.bloodjournal.org/content/132/4/393 
|
| Verfasserangaben: | Jorge E. Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp D. le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H. Jean Khoury, Moshe Talpaz, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C. Müller, Carlo Gambacorti-Passerini, Stephanie Lustgarten, Victor M. Rivera, Frank G. Haluska, François Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, Neil P. Shah, and Hagop M. Kantarjian |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1668118572 | ||
| 003 | DE-627 | ||
| 005 | 20220816180548.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190628s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood-2016-09-739086 |2 doi | |
| 035 | |a (DE-627)1668118572 | ||
| 035 | |a (DE-599)KXP1668118572 | ||
| 035 | |a (OCoLC)1341229416 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Cortés, Jorge Eduardo |d 197X- |e VerfasserIn |0 (DE-588)140388567 |0 (DE-627)61826423X |0 (DE-576)316680826 |4 aut | |
| 245 | 1 | 0 | |a Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia |b final 5-year results of the phase 2 PACE trial |c Jorge E. Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp D. le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H. Jean Khoury, Moshe Talpaz, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C. Müller, Carlo Gambacorti-Passerini, Stephanie Lustgarten, Victor M. Rivera, Frank G. Haluska, François Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, Neil P. Shah, and Hagop M. Kantarjian |
| 264 | 1 | |c [26 July 2018] | |
| 300 | |b Diagramme | ||
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.06.2019 | ||
| 520 | |a Visual Abstract - <img class="highwire-fragment fragment-image" alt="Figure1" src="http://www.bloodjournal.org/content/bloodjournal/132/4/393/F1.medium.gif" width="440" height="294"/>Download figureOpen in new tabDownload powerpoint - - Ponatinib has potent activity against native and mutant BCR-ABL1, including BCR-ABL1T315I. The pivotal phase 2 Ponatinib Ph+ ALL and CML Evaluation (PACE) trial evaluated efficacy and safety of ponatinib at a starting dose of 45 mg once daily in 449 patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) resistant/intolerant to dasatinib or nilotinib, or with BCR-ABL1T315I. This analysis focuses on chronic-phase CML (CP-CML) patients (n = 270) with 56.8-month median follow-up. Among 267 evaluable patients, 60%, 40%, and 24% achieved major cytogenetic response (MCyR), major molecular response (MMR), and 4.5-log molecular response, respectively. The probability of maintaining MCyR for 5 years was 82% among responders. Dose reductions were implemented in October 2013 to decrease the risk of arterial occlusive events (AOEs); ≥90% of CP-CML patients who had achieved MCyR or MMR maintained response 40 months after elective dose reductions. Estimated 5-year overall survival was 73%. In CP-CML patients, the most common treatment-emergent adverse events were rash (47%), abdominal pain (46%), thrombocytopenia (46%), headache (43%), dry skin (42%), and constipation (41%). The cumulative incidence of AOEs in CP-CML patients increased over time to 31%, while the exposure-adjusted incidence of new AOEs (15.8 and 4.9 per 100 patient-years in years 1 and 5, respectively) did not increase over time. These final PACE results demonstrate ponatinib provides durable and clinically meaningful responses, irrespective of dose reductions, in this population of heavily pretreated CP-CML patients. This trial was registered at www.clinicaltrials.gov as #NCT01207440. | ||
| 700 | 1 | |a Müller, Martin Christian |d 1972- |e VerfasserIn |0 (DE-588)121360296 |0 (DE-627)705409236 |0 (DE-576)181482819 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d Washington, DC : American Society of Hematology, 1946 |g 132(2018), 4, Seite 393-404 |h Online-Ressource |w (DE-627)266886647 |w (DE-600)1468538-3 |w (DE-576)075961938 |x 1528-0020 |7 nnas |a Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia final 5-year results of the phase 2 PACE trial |
| 773 | 1 | 8 | |g volume:132 |g year:2018 |g number:4 |g pages:393-404 |g extent:12 |a Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia final 5-year results of the phase 2 PACE trial |
| 856 | 4 | 0 | |u https://doi.org/10.1182/blood-2016-09-739086 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.bloodjournal.org/content/132/4/393 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190628 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 121360296 |a Müller, Martin Christian |m 121360296:Müller, Martin Christian |d 60000 |d 61200 |e 60000PM121360296 |e 61200PM121360296 |k 0/60000/ |k 1/60000/61200/ |p 15 | ||
| 999 | |a KXP-PPN1668118572 |e 3490208862 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"noteIll":"Diagramme","extent":"12 S."}],"relHost":[{"title":[{"subtitle":"journal of the American Society of Hematology","title":"Blood","title_sort":"Blood"}],"part":{"pages":"393-404","issue":"4","year":"2018","extent":"12","volume":"132","text":"132(2018), 4, Seite 393-404"},"titleAlt":[{"title":"Blood online"}],"pubHistory":["1.1946 -"],"language":["eng"],"corporate":[{"roleDisplay":"Herausgebendes Organ","display":"American Society of Hematology","role":"isb"}],"recId":"266886647","disp":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia final 5-year results of the phase 2 PACE trialBlood","type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 21.04.2023"],"id":{"zdb":["1468538-3"],"eki":["266886647"],"issn":["1528-0020"]},"origin":[{"dateIssuedDisp":"1946-","dateIssuedKey":"1946","publisher":"American Society of Hematology ; Saunders ; HighWire Press","publisherPlace":"Washington, DC ; Philadelphia, Pa. ; Stanford, Calif."}],"physDesc":[{"extent":"Online-Ressource"}]}],"origin":[{"dateIssuedDisp":"[26 July 2018]","dateIssuedKey":"2018"}],"id":{"doi":["10.1182/blood-2016-09-739086"],"eki":["1668118572"]},"name":{"displayForm":["Jorge E. Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp D. le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H. Jean Khoury, Moshe Talpaz, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C. Müller, Carlo Gambacorti-Passerini, Stephanie Lustgarten, Victor M. Rivera, Frank G. Haluska, François Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, Neil P. Shah, and Hagop M. Kantarjian"]},"note":["Gesehen am 28.06.2019"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"recId":"1668118572","title":[{"title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia","subtitle":"final 5-year results of the phase 2 PACE trial","title_sort":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia"}],"person":[{"role":"aut","roleDisplay":"VerfasserIn","display":"Cortés, Jorge Eduardo","given":"Jorge Eduardo","family":"Cortés"},{"family":"Müller","given":"Martin Christian","display":"Müller, Martin Christian","roleDisplay":"VerfasserIn","role":"aut"}]} | ||
| SRT | |a CORTESJORGPONATINIBE2620 | ||